(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 12.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.63%.
Mimedx Group's revenue in 2025 is $342,805,000.On average, 1 Wall Street analysts forecast MDXG's revenue for 2025 to be $55,104,829,875, with the lowest MDXG revenue forecast at $55,104,829,875, and the highest MDXG revenue forecast at $55,104,829,875.
In 2026, MDXG is forecast to generate $63,186,871,590 in revenue, with the lowest revenue forecast at $63,186,871,590 and the highest revenue forecast at $63,186,871,590.